Payment overview · 2025
General Payments
$78,769.06
134 reported records · 14 companies
Healthcare provider profile · identity verified
Lingling Du, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · NEW ORLEANS, LA · NPI 1003103532
Verified facts
What the public records show
CMS Open Payments records show Lingling Du, M.D. received $78,769.06 in general payments during 2025 across 134 reported records.
Exelixis Inc. accounted for 45.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Cabometyx, Xermelo.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
Exelixis Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABOMETYX as an associated drug or biological on 11749 records involving 4526 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Cabometyx by this doctor in 2024.
TerSera Therapeutics LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xermelo as an associated drug or biological on 1332 records involving 974 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xermelo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exelixis Inc. | Unresolved — no canonical attribution shown | $35,753.98 | 45.4% | 69 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $33,997.85 | 43.2% | 41 | 2025 |
| Sirtex Medical Inc | Unresolved — no canonical attribution shown | $4,548.48 | 5.8% | 7 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $2,007.72 | 2.5% | 4 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $1,100.00 | 1.4% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $790.00 | 1.0% | 1 | 2025 |
| Intera Oncology, Inc | Unresolved — no canonical attribution shown | $201.88 | 0.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $180.52 | 0.2% | 2 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $83.30 | 0.1% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $25.99 | 0.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $20.25 | 0.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.18 | 0.0% | 1 | 2025 |
| BeiGene USA, Inc. | Unresolved — no canonical attribution shown | $19.51 | 0.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.40 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $30,162.50 | 17 |
| Compensation for serving as faculty or as a speaker for a medical education program | $27,072.50 | 9 |
| Travel and Lodging | $12,397.27 | 59 |
| Consulting Fee | $6,840.00 | 4 |
| Food and Beverage | $2,296.79 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $35,579.07 | 68 | 2025 |
Source payment records
|
|||||
| TheraSphere Y90 Glass Microspheres 10 GBq Normalized: therasphere y90 glass microspheres 10 gbq |
Device | Boston Scientific Corporation | $14,814.73 | 21 | 2025 |
Source payment records
|
|||||
| TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial) Normalized: therasphere y90 glass microspheres 7 0 gbq us commercial |
Device | Boston Scientific Corporation | $12,397.07 | 15 | 2025 |
Source payment records
|
|||||
| General - Interventional Oncology Normalized: general interventional oncology |
Device | Boston Scientific Corporation | $6,773.71 | 4 | 2025 |
Source payment records
|
|||||
| SIR-Spheres Microspheres Normalized: sir spheres microspheres |
Device | Sirtex Medical Inc | $4,548.48 | 7 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $1,100.00 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $790.00 | 1 | 2025 |
Source payment records
|
|||||
| INTERA Normalized: intera |
Device | Intera Oncology, Inc | $201.88 | 1 | 2025 |
Source payment records
|
|||||
| Xermelo Normalized: xermelo |
Drug | TerSera Therapeutics LLC | $83.30 | 3 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc., BeiGene USA, Inc. | $56.51 | 3 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $25.99 | 1 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $20.72 | 1 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| TheraSphere Administration Set Normalized: therasphere administration set |
Device | Boston Scientific Corporation | $12.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CABOMETYX cabometyx |
2025 | Cabometyx | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Xermelo xermelo |
2025 | Xermelo | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | 16 |
| Exelixis Inc. Exact reporting entity; no affiliate inference |
2025 | CABOMETYX open payments reported associated product |
CMS Open Payments — General Payments 11749 supporting records · 4526 recipient NPIs · example record 1218789893 |
Cabometyx · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| TerSera Therapeutics LLC Exact reporting entity; no affiliate inference |
2025 | Xermelo open payments reported associated product |
CMS Open Payments — General Payments 1332 supporting records · 974 recipient NPIs · example record 1244053204 |
Xermelo · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ondansetron Odt | Ondansetron | 75 | 50 |
| Oxycodone Hcl | Oxycodone Hcl | 51 | 28 |
| Eliquis | Apixaban | 45 | 16 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 45 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | suppressed |
| Letrozole | Letrozole | 43 | 11 |
| Olanzapine | Olanzapine | 40 | 25 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 36 | 19 |
| Promethazine Hcl | Promethazine Hcl | 36 | 25 |
| Creon | Lipase/Protease/Amylase | 30 | suppressed |
| Gabapentin | Gabapentin | 30 | 12 |
| Enoxaparin Sodium | Enoxaparin Sodium | 27 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 27 | 20 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | 12 |
| Xermelo | Telotristat Etiprate | 22 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 20 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 20 | 13 |
| Amlodipine Besylate | Amlodipine Besylate | 18 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 17 | suppressed |
| Dexamethasone | Dexamethasone | 16 | 11 |
| Famotidine | Famotidine | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Everolimus | Everolimus | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Cabometyx | Cabozantinib S-Malate | 13 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 12 | suppressed |
| Nubeqa | Darolutamide | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $78,769.06 · 134 records | Exelixis Inc. | BRUKINSA, CABOMETYX, FRUZAQLA, General - Interventional Oncology, INTERA, Lenvima, OPDIVO, SCEMBLIX, SIR-Spheres Microspheres, TEVIMBRA, TheraSphere Administration Set, TheraSphere Y90 Glass Microspheres 10 GBq, TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial), Vyloy, Xermelo, ZYNYZ | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Cabometyx play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error